Salvia miltiorrhiza Bunge (Danshen), a common medicinal plant in traditional Chinese medicine, has been tested effectively to prevent urolithiasis in animals; nevertheless, the clinical application for urolithiasis remains unclear. We thus investigated the clinical effect of Danshen by analyzing the database from the Taiwan National Institute of Health. The cohort “Danshen-users” was prescribed Chinese herb medicine Danshen after the initial diagnosis of calculus. The control group (non-Danshen-users) was not given Danshen after the initial diagnosis of calculus. The date of first using Danshen after new diagnosis date of calculus was considered as index date. The outcome variables were categorized into two categories: the first category included calculus surgical treatment, including extracorporeal shock wave lithotripsy, ureteroscopy, percutaneous nephrostomy with fragmentation, and ureterolithotomy; the second category included any bleeding disorders, including gastrointestinal bleeding, intracranial hemorrhage, and blood transfusions. The incidence of calculus surgical treatment in the Danshen-users was less than that in the non-Danshen-users: 1.071% in 1,000 person-years (200 people followed up for 5 years) and 3.142% in 1,000 person-years, respectively. The adjusted hazard ratio for calculus surgical treatment in the Danshen-users was 0.34 (95% confidence intervals: 0.31–0.38) as compared to the non-Danshen-users. When stratified by sex, the incidence of calculus surgical treatment in Danshen-users was 0.685% in 1,000 person-years and 1.575% in 1,000 person-years for women and men, respectively, which was lower than that in non-Danshen-users. Danshen decreased the ratio of subsequent stone treatment after the first treatment in the study population; there was no increased bleeding risk due to long-term Danshen use.

1. Introduction

Urolithiasis is a common urological disorder with an annual incidence of 7–13% in North America, 1–5% in Asia [1, 2], and 6.4% in Taiwan [3]. Urolithiasis is also a disease with high recurrence. Over 50% of the patients with stone experience stone episode recurrence after 5 years of their first treatment [4]. Therefore, seeking drugs for the prevention of stone recurrence is an important issue.
Salvia miltiorrhiza Bunge (Danshen) is a common medicinal plant in traditional Chinese medicine (TCM) with its roots (dried) possessing pharmacological properties [5]. Danshen is a classical Huoxue Huayu herb (a TCM term used for activating blood circulation, relieving pain, activating blood to promote menstruation, clearing heart fire, tranquilizing, and treating blood stasis) that has been prescribed clinically for one thousand years [6]. In modern medicine, Danshen is used for the treatment of cardiovascular diseases [7, 8], osteoporosis [9], anticancer [5], and hepatoprotective effect [9]. Danshen is one of the tested effective TCM herbs for prevention of stone disease in our previous study [10, 11]. We chose Danshen (as an herb to be tested) because of its effectiveness in the treatment of blood disorders. According to TCM, blood stasis is one of the major pathogenes of stone disease, and hematuria is frequently observed in patients with stones.

We used the database from the National Institutes of Health (NIH), Taiwan, to study the clinical effect of the potential TCM herb on urolithiasis. Although Danshen has been tested effectively for the prevention of urolithiasis in animal models [11], the clinical application in the prevention of urolithiasis is still under investigation [12]. The objective of the present study was to investigate the preventive effect of Danshen clinically by analyzing the NIH database. The surrogate outcome will be a decrease in the number of stone surgeries in a cohort. We have also studied the possible effects of increased bleeding tendency due to the antiplatelet effect of Danshen used for treating blood stasis.

2. Materials and Methods

2.1. Database. For this retrospective cohort study, our data source was from National Health Insurance Research Database (NHIRD) in Taiwan. Taiwan’s National Health Insurance (NHI) program is a compulsory insurance that has been providing comprehensive coverage to 99% of 23 million individuals since 1996. The NHIRD included information of sex, birthday, outpatient care, inpatients care, western and traditional Chinese medicine (TCM) prescription, medical institutions, and registration files with scrambled identifications. We used the LHID 2000 (Longitudinal Health Insurance Database 2000), which contains medicine information between 1996 and 2013 of 1 million beneficiaries randomly sampled from the registry of all beneficiaries in 2000. The sampled patients exhibit no significant difference in age, sex, birth year, or average insured payroll-related amount from the general population. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used for diagnoses. Because the NHIRD contains identified secondary data for research, the present study was waived from informed consent. A disease diagnosis without valid supporting clinical findings may be considered a medical fraud by NHI with a penalty of 100 times of the payment claimed by the treating physician or hospital. This study was approved by the Institutional Review Board of China Medical University (CMUH104-REC2-115).

2.2. Study Population. All cases diagnosed with calculus (ICD-9-CM: 592.0, 592.1, and 592.9) from January 2000 to December 2010 and aged ≥18 years were the study cohort population. The case cohort population was defined as patients who were orally given (either single or formula form) herbal medicine powder Danshen after initial diagnosis of calculus. Patients did not use Danshen after initial diagnosis date of calculus as compared to cohort group. The date of first using Danshen after new diagnosis date of calculus was considered as index date.

2.3. Covariate Assessment. Sociodemographic factors included age and sex. Age was divided into 3 groups: 18–39 years old, 40–64 years old, and ≥65 years old. Baseline comorbidities were considered if ICD-9-CM codes appeared at least once in outpatients or inpatients before initial fibromyalgia diagnosis, including diabetes mellitus (ICD-9-CM: 250), hypertension (ICD-9-CM: 401–405), urinary tract infection (ICD-9-CM: 599.0), chronic kidney disease (ICD-9-CM: 585), and gout (ICD-9-CM: 274.9).

2.4. Primary Outcome. The outcome variables were two: one was calculus surgical treatment, including extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, percutaneous nephrostomy with fragmentation (PCNL), and ureterolithotomy, and the other was any bleeding disorders, including gastrointestinal bleeding (ICD-9-CM: 578.0, 578.1, 578.9), intracranial hemorrhage (ICH, ICD-9-CM: 432.0, 432.9), and blood transfusions (OP code: 99.0). Each individual was assessed from the index date to 31 December 2013 (end of the study) until the time of diagnosis of calculus surgical treatment or any bleeding disorders or until the patients were censored for withdrawal from insurance or lost to follow-up (which one first occurs).

2.5. Statistical Analyses. Student’s t-tests for continuous variables and Chi-square test for categorical variables were used to compare the two study groups. We estimated hazard ratios (HRs) and 95% confidence intervals (CI) of calculus surgical treatment and bleeding disorder for the cohort using Danshen compared to the cohort not using Danshen by Cox proportional hazard model. Statistical analysis was performed and figures were created using SAS 9.4 (SAS Institute, Cary, NC) and R software. P < 0.05 in two-tailed tests indicated statistical significance.

3. Results

Our study included a total of 8,568 patients using Danshen (Danshen-users) and 56,502 patients not using Danshen (non-Danshen-users) suffering from calculus disease [after frequency matching (1:1) through sex, age (per 5 years), initial diagnosis year of calculus, and index year]. There were 8,536 Danshen-users and non-Danshen-users in each cohort. Table 1 shows the characteristics of both groups. The mean age (standard deviation, SD) for Danshen-users and non-Danshen-users was 46.40 (14.29) years and 46.42 (14.30) years, respectively. After frequency matching, the distribution of sex and age was not significantly different (P =
### Table 1: Characteristics of calculus patients according to use or no use of Danshen.

| Variable                          | Using Danshen in calculus patients |          |          | P value* |
|-----------------------------------|------------------------------------|----------|----------|----------|
|                                   | No (n = 8536)                      | Yes (n = 8536) |          |          |
|                                   | n | %     | n | %     |          |
| Sex                               |   |       |   |       | 0.99    |
| Female                            | 4723 | 55.33 | 4723 | 55.33 |          |
| Male                              | 3813 | 44.67 | 3813 | 44.67 |          |
| Age group, years                  |          |          | 0.99    |          |
| 18–39                             | 3018 | 35.36 | 3018 | 35.36 |          |
| 40–64                             | 4508 | 52.81 | 4508 | 52.81 |          |
| ≥65                               | 1010 | 11.83 | 1010 | 11.83 |          |
| Mean ± SD (years)                 | 46.42(14.30) |          | 46.40(14.29) | 0.9157 |
| Baseline comorbidities            |          |          |          | <0.0001 |
| Diabetes mellitus                 | 2992 | 35.05 | 3339 | 39.12 |          |
| Urinary tract infection           | 4897 | 57.37 | 5241 | 61.4  |          |
| Hypertension                      | 4402 | 51.57 | 4561 | 53.43 | 0.0148  |
| Chronic kidney disease            | 657  | 7.7   | 753  | 8.82  |          |
| Gout                              | 1608 | 18.84 | 1811 | 21.22 |          |
| Duration between diagnosis date of calculus and index, days (mean, median) | 1120 (923) | 1130 (921) | 0.4553* |

*Chi-square test; †t-test. The mean (median) follow-up period was 6.27 (5.98) years and 5.09 (4.86) years for cohort group using Danshen and cohort group not using Danshen, separately.

0.99 for both) between Danshen-users and non-Danshen-users. The proportion of baseline comorbidities in Danshen-users was higher than that in non-Danshen-users (P < 0.05 for all). The mean (median) follow-up period for Danshen-users and non-Danshen-users was 6.27 (5.98) years and 5.09 (4.86) years, respectively.

The incidence of calculus surgical treatment in the Danshen-users was less than that in the non-Danshen-users, 1.071% in 1,000 person-years (200 people followed up for 5 years) and 3.142% in 1,000 person-years, respectively. The adjusted hazard ratio (HR) for calculus surgical treatment in the Danshen-users was 0.34 (95% CI: 0.31–0.38) as compared to the non-Danshen-users. When stratifying by sex, the incidence of calculus surgical treatment in the Danshen-users was 0.685% in 1,000 person-years and 1.575% in 1,000 person-years for women and men, respectively, which was lower than that in the non-Danshen-users (2.454% in 1,000 person-years and 4.070% in 1,000 person-years for women and men, resp.).

When stratifying by age, the incidence of calculus surgical treatment in Danshen-users was 1.087% in 1,000 person-years, 1.137% in 1,000 person-years, and 0.690% in 1,000 person-years for 18–39 years age group, 40–64 years age group, and above 65 years age group, respectively, which was lower than that in the non-Danshen-users (2.675% in 1,000 person-years, 3.514% in 1,000 person-years, and 2.989% in 1,000 person-years for 18–39 years age group, 40–64 years age group, and above 65 years age group, resp.). The adjusted HRs revealed a significantly lower risk of calculus surgical treatment in the Danshen-users as compared to the non-Danshen-users in all the categories: women, men, age group of 18–39 years, age group of 40–64 years, and age group above 65 years population (Table 2). The estimated cumulative incidence of calculus surgical treatment in the Danshen-users was lower than that in the non-Danshen-users (P < 0.0001, log-rank test) (Figure 1).

The incidence of any bleeding disorder in the Danshen-users was less than that in the non-Danshen-users (1.708% in 1000 person-years and 2.577% in 1,000 person-years, resp.).
Table 2: Incidence rates, hazard ratio, and confidence intervals of calculus surgical treatment and any bleeding disorder for calculus patients using and not using Danshen in the stratification of sex and age.

| Variables                      | Using Danshen in calculus patients | Crude HR | Adjusted HR† |
|--------------------------------|------------------------------------|----------|--------------|
|                                | Event Person-years IR               | Event Person-years IR | (95% CI)       | (95% CI)       |
| **Outcome: calculus surgical treatment** |                                     |          |              |
| Total                          | 1370 43605 31.42 574 53589 10.71 | 0.36 (0.33–0.4) 0.34 (0.31–0.38) |
| Sex                            |                                     |          |              |
| Female                         | 615 25057 24.54 208 30354 6.85 | 0.3 (0.26–0.35) 0.29 (0.24–0.34) |
| Male                           | 755 18548 40.70 366 23235 15.75 | 0.41 (0.36–0.47) 0.39 (0.34–0.44) |
| **Age group, years**           |                                     |          |              |
| 18–39                          | 449 16784 26.75 215 19782 10.87 | 0.43 (0.36–0.5) 0.4 (0.34–0.47) |
| 40–64                          | 799 22739 35.14 320 28151 11.37 | 0.35 (0.3–0.39) 0.33 (0.29–0.38) |
| ≥65                            | 122 4082 29.89 39 5656 6.90 | 0.26 (0.18–0.37) 0.25 (0.17–0.35) |
| **Outcome: any bleeding disorders** |                                     |          |              |
| Total                          | 1138 44166 25.77 917 53678 17.08 | 0.66 (0.61–0.72) 0.61 (0.56–0.67) |
| Sex                            |                                     |          |              |
| Female                         | 572 25341 22.57 463 30379 15.24 | 0.68 (0.6–0.77) 0.63 (0.56–0.71) |
| Male                           | 566 18824 30.07 454 23299 19.49 | 0.64 (0.57–0.73) 0.59 (0.52–0.67) |
| **Age group, years**           |                                     |          |              |
| 18–39                          | 202 16862 11.98 162 19786 8.19 | 0.68 (0.56–0.84) 0.65 (0.53–0.8) |
| 40–64                          | 629 23102 27.23 516 28238 18.27 | 0.67 (0.59–0.75) 0.63 (0.56–0.71) |
| ≥65                            | 307 4202 73.07 239 5653 42.28 | 0.58 (0.49–0.69) 0.55 (0.46–0.65) |

IR, incidence rates per 1,000 person-years; HR, hazard ratio; CI, confidence interval. Adjusted HR† represented adjusted hazard ratio: mutually adjusted for Danshen drug used, sex, age, diabetes mellitus, urinary tract infection, hypertension, chronic kidney disease, and gout in Cox proportional hazard regression. ***P < 0.001.

The adjusted HR for calculus surgical treatment in Danshen-users was 0.61 (95% CI: 0.56–0.67) as compared to the non-Danshen-users. When stratifying by sex, the incidence of any bleeding disorder in the Danshen-users was 1.524% in 1,000 person-years and 1.949% in 1,000 person-years for women and men, respectively, which was lower than that in the non-Danshen-users (2.557% in person-years and 3.007% in 1,000 person-years for women and men, resp.).

When stratifying by age, the incidence of calculus surgical treatment in Danshen-users was 0.819% in 1,000 person-years, 1.827% in 1,000 person-years, and 4.228% in 1,000 person-years for 18–39 years age group, 40–64 years age group, and above 65 years age group, respectively, which was lower than that in the non-Danshen-users (1.198% in 1,000 person-years, 2.723% in 1,000 person-years, and 7.307% in 1,000 person-years for 18–39 years age group, 40–64 years age group, and above 65 years group, resp.). The adjusted HRs revealed a significantly lower risk of any bleeding disorder in the Danshen-users as compared to the non-Danshen-users in all the categories: females, males, age group of 18–39 years, age group of 40–64 years, and above 65 years age group population (Table 2). The estimated cumulative incidence of any bleeding disorder in the Danshen-users was lower than that in the non-Danshen-users (P < 0.0001, log-rank test) (Figure 2). The HRs and 95% CI of calculus surgical treatment and any bleeding disorder associated with cumulative dose per year of Danshen among calculus patients with Danshen-users were shown in Table 3.

4. Discussion

We observed that Danshen significantly reduces the subsequent surgical treatment after the first stone episode, with a hazard ratio of 0.34. This effect was consistent in both sexes and among all age groups. Danshen may prove to be clinically effective for those having stone disease and seeking a measure to prevent their further surgical treatment. Danshen poses a concern regarding the increased bleeding tendency due to its enhanced blood stasis effect. However, we did not find any incidence involving hemorrhage or any transfusion event in this cohort. This result suggests that long-term use of Danshen may prove to be safe without any bleeding disorder.

The idea of using Danshen in the present study originated from our previous data [11]. Danshen revealed its preventive results for the crystal formation in a fruit fly (as observed in an animal study). *Salvia miltiorrhiza* appeared in the classic herbal book named “Shennong Ben Cao Jing” more than 2000 years ago (about 200 and 250 AD) [13]. It was described as a noble and nontoxic herb. It is often used to treat cardiovascular diseases [14, 15], hypertension, and ischemic stroke due to its efficacy on blood circulation [16, 17]. Till date, more than thirty pharmaceutical preparations for the treatment of cardiovascular diseases have been developed in clinical practice [18]. Cardiac and renal dysfunctions often occur simultaneously due to the shared causes and pathogenesis [19]. Furthermore, oxidative stress is considered as the most important determinant of the common cause [20].
Table 3: Hazard ratios and 95% confidence intervals of calculus surgical treatment and any bleeding disorder associated with cumulative dose per year of Danshen among calculus patients using Danshen.

| Used Danshen dose (g) per year | n   | Number of events | Hazard ratio (95% CI) | Crude       | Adjusted†  |
|-------------------------------|-----|------------------|-----------------------|-------------|------------|
| **Event: calculus surgical treatment** |     |                  |                       |             |            |
| Less than 417 g per year      | 2813| 203              | 1 (reference)         | 1 (reference)|            |
| 417–1096 g per year           | 3025| 179              | 0.75 (0.62–0.92)**    | 0.76 (0.62–0.93)**    |
| More than 1096 g per year     | 2698| 192              | 0.92 (0.75–1.12)      | 0.94 (0.77–1.14)     |
| **Event: any bleeding disorders** |     |                  |                       |             |            |
| Less than 417 g per year      | 2813| 306              | 1 (reference)         | 1 (reference)|            |
| 417–1096 g per year           | 3025| 308              | 0.84 (0.71–0.98)*     | 0.83 (0.71–0.97)*     |
| More than 1096 g per year     | 2698| 303              | 0.94 (0.80–1.10)      | 0.95 (0.81–1.11)     |

Adjusted HR† represented adjusted hazard ratio: mutually adjusted for sex, age, diabetes mellitus, urinary tract infection, hypertension, chronic kidney disease, and gout in Cox proportional hazard regression; *P < 0.05; **P < 0.01; tertiles are two cut points that will divide a dataset into three equal-sized groups. 417 g was 33rd percentage point and 1096 g was 66th percentage.

Figure 2: The estimated cumulative incidence of any bleeding disorder in the Danshen-users was lower than that in the non-Danshen-users by Kaplan-Meier analysis.

The hypertensive patients have a greater risk of kidney stones than those with normal blood pressure. The patients with kidney stones are more likely to suffer from hypertension than those without urolithiasis. Thus, there exists a positive correlation between hypertension and renal stones [21]. According to a recent study, Danshen is the most frequently prescribed single herb drug for hypertension [22]. In addition, previous animal studies revealed that overproduction of reactive oxygen species causes kidney damage, and *Salvia miltiorrhiza* helps to improve the renal function and prevent oxidative stress in the renal tissues, thereby treating the renal damage [23–26].

Our previous study conducted with an emerging translational model to screen antilithic herbal drugs revealed the inhibitory effect of Danshen on the formation of CaO_4_ crystals in the Malpighian tubules of *Drosophila* [11]. According to the epidemiological studies, urolithiasis is associated with many chronic diseases including obesity, metabolic syndrome, diabetes, hypertension, chronic kidney disease, and coronary artery disease [27–32]. The correlation between these chronic diseases and renal stones is most likely the result of a common pathophysiological mechanism. Reactive oxygen species (ROS) and oxidative stress are the common features between kidney stones and venereal diseases [33]. Further evidences showed that ROS is also produced in idiopathic CaO_4_ kidney stones. A kidney stone is not only a physical-chemical event but also a metabolic disorder. The chronic diseases associated with oxidative stress are related to each other. Oxidative stress is usually caused by one disorder, which in turn contributes to the development of another disorder, particularly hypertension and diabetes. Both these effects may lead to oxidative stress, kidney damage, and inflammation, along with the changes in the urinary environment which promote crystallization [21]. Therefore, the treatment of urinary tract stones should not be overlooked, and the original source must be cured completely. Furthermore, TCM focuses on the reconstruction of the homeostasis prior to the formation of stones, along with acting as a treatment of urolithiasis after kidney disease and stone formation [34]. Therefore, Danshen may play an important role in the prevention of urolithiasis.

The limitations of this study include limited patient number, a surrogate outcome instead of recurrence, and unknown stonesite and number. In addition, calculus surgical treatment option depends on stone size. However, LHID 2000 does not provide the information of stone size.

5. Conclusions

Danshen decreased the ratio of subsequent stone treatment after the first treatment in a population study from Taiwan’s database. Long-term use of Danshen may prove to be safe
with a reduced risk of a bleeding event. Therefore, Danshen is a safe herb having a potential for the prevention of calculus.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This work was supported in part by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital, Academia Sinica Stroke Biosignature Project (BM1070101021), MOST Clinical Trial Consortium for Stroke (MOST106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Katsuzo and Kiyo Aoshima Memorial Funds, Japan, China Medical University (CMU106-S-22 and CMU106-S-32), CMU under the Aim for Top University Plan of the Taiwan Ministry of Education, and Taiwan Ministry of Science and Technology (MOST104-2320-B039-016-MY3 and MOST106-2813-C-039-108-B).

References
[1] M. Ilhan, B. Ergene, I. Sünart et al., “Preclinical evaluation of antiurolithiatic activity of Viburnum opulus L. on sodium oxalate-induced urolithiasis rat model,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 578103, pp. 1-10, 2014.

[2] A. Premgamone, P. Sriboonlue, S. Maskasem, W. Ditsataporn-charoen, and B. Jindawong, “Orthosiphon versus placebo in nephrolithiasis with multiple chronic complaints: a randomized control trial,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 4, pp. 495–501, 2009.

[3] W.-Y. Huang, Y.-F. Chen, S. Carter, H.-C. Chang, C.-F. Lan, and K.-H. Huang, “Epidemiology of upper urinary tract stone disease in a Taiwanese population: a nationwide, population based study,” The Journal of Urology, vol. 189, no. 6, pp. 2158–2163, 2013.

[4] K. K. Stamatakou, M. E. Francis, C. A. Jones, L. M. Nyberg Jr., and G. C. Curhan, “Time trends in reported prevalence of kidney stones in the United States: 1976–1994,” Kidney International, vol. 63, no. 5, pp. 1817–1823, 2003.

[5] X. Chen, J. Guo, J. Bao, J. Lu, and Y. Wang, “The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review,” Medicinal Research Reviews, vol. 34, no. 4, pp. 768–794, 2014.

[6] Y. Guo, Y. Li, L. Xue et al., “Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs,” Journal of Ethnopharmacology, vol. 155, no. 3, pp. 1401–1416, 2014.

[7] Y.-H. Chen, S.-J. Lin, H.-H. Ku et al., “Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-α-treated human aortic endothelial cells,” Journal of Cellular Biochemistry, vol. 82, no. 3, pp. 512–521, 2001.

[8] T.-L. Yang, F.-Y. Lin, Y.-H. Chen et al., “Salvianolic acid B inhibits low-density lipoprotein oxidation and neointimal hyperplasia in endothelium-denuded hypercholesterolemic rabbits,” Journal of the Science of Food and Agriculture, vol. 91, no. 1, pp. 134–141, 2011.

[9] Y. Yuan, Q. Wu, J.-S. Shi, and X.-P. Chen, “Advance in studies on hepatoprotective effect of Salvia miltiorrhiza and its main components,” China Journal of Chinese Materia Medica, vol. 40, no. 4, pp. 588–593, 2015.

[10] Y. Chen, H. Liu, H. Chen et al., “Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/uro lithiasis,” Kidney International, vol. 80, no. 4, pp. 369–377, 2011.

[11] S. Y. Wu, J. L. Shen, K. M. Man et al., “An emerging translational model to screen potential medicinal plants for nephrolithiasis, an independent risk factor for chronic kidney disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 972958, pp. 1–7, 2014.

[12] C. Pan, H. Huang, M. Chen et al., “Lower risk of end stage renal disease in diabetic nurse,” Biomedicine, vol. 7, no. 4, article 25, 2017.

[13] Z. Shang, “Discussion on the date of appearance of the title Shen nong ben caoqings (Shennong’s Herbal Classic),” Zhonghua Yi Shi Za Zhi, vol. 29, no. 3, pp. 135–138, 1999.

[14] M. Asokan Shibu, W. Kuo, C. Kuo et al., “Potential phytoestrogen alternatives exert cardio-protective mechanisms,” Biomedicine, vol. 7, no. 2, article 11, 2017.

[15] J. Yang, C. Lu, S. Kuo et al., “Autophagy and its link to type II diabetes mellitus,” Biomedicine, vol. 7, no. 2, article 8, 2017.

[16] K. Wang, D. Zhang, J. Wu, S. Liu, X. Zhang, and B. Zhang, “A comparative study of Danhong injection and Salvia miltiorrhiza injection in the treatment of cerebral infarction,” Medicine, vol. 96, no. 22, Article ID e7079, 2017.

[17] X. Li, Y. Luo, L. Wang et al., “Acute and subacute toxicity of ethanol extracts from Salvia przewalskii Maxim in rodents,” Journal of Ethnopharmacology, vol. 131, no. 1, pp. 110–115, 2010.

[18] Z. You, Y. Xin, Y. Liu et al., “Protective effect of Salvia Miltiorrhiza Bunge on renal injury induced by myocardial ischemia and reperfusion,” Asian Journal of Medicinal Research, vol. 34, no. 4, pp. 1094–1098, 2017.

[19] X. Lu, Y. Jin, L. Ma, and L. Du, “Danshen (Radix Salviae Miltiorrhizae) reverses renal injury induced by myocardial infarction,” Journal of Traditional Chinese Medicine, vol. 35, no. 3, pp. 306–311, 2015.

Evidence-Based Complementary and Alternative Medicine
[26] L. Li, Y. Zhang, J. Ma et al., "Salvia miltiorrhiza injection ameliorates renal damage induced by lead exposure in mice," The Scientific World Journal, vol. 2014, Article ID 572697, pp. 1–9, 2014.

[27] S. H. Obligado and D. S. Goldfarb, "The association of nephrolithiasis with hypertension and obesity: a review," American Journal of Hypertension, vol. 21, no. 3, pp. 257–264, 2008.

[28] I. G. Jeong, T. Kang, J. K. Bang et al., "Association between metabolic syndrome and the presence of kidney stones in a screened population," American Journal of Kidney Diseases, vol. 58, no. 3, pp. 383–388, 2011.

[29] J. C. Lieske, L. S. P. de la Vega, M. T. Gettman et al., "Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study," American Journal of Kidney Diseases, vol. 48, no. 6, pp. 897–904, 2006.

[30] N. A. Saucier, M. K. Sinha, K. V. Liang et al., "Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota," American Journal of Kidney Diseases, vol. 55, no. 1, pp. 61–68, 2010.

[31] M. Daudon and P. Jungers, "Diabetes and nephrolithiasis," Current Diabetes Reports, vol. 7, no. 6, pp. 443–448, 2007.

[32] A. D. Rule, V. L. Roger, L. J. Melton III et al., "Kidney stones associate with increased risk for myocardial infarction," Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1641–1644, 2010.

[33] S.-J. Lin, T.-H. Yang, Y.-H. Chen et al., "Effects of Ginkgo biloba extract on the proliferation of vascular smooth muscle cells in vitro and on intimal thickening and interleukin-1 β expression after balloon injury in cholesterol-fed rabbits in vivo," Journal of Cellular Biochemistry, vol. 85, no. 3, pp. 572–582, 2002.

[34] M. D. I. Gohel and S. P. Wong, "Chinese herbal medicines and their efficacy in treating renal stones," Urolithiasis, vol. 34, no. 6, pp. 365–372, 2006.